Skip to main content

Table 5 Relationship between clinical characteristics and OS/DFS in patients with high HBV DNA level (≥2000 IU/mL), as determined by univariate and multivariate Cox regression analysis

From: Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection

Variable OS DFS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR P value HR (95 % CI) P value HR P value HR (95 % CI) P value
Age (≥50 vs. <50 years) 1.329 0.186    1.384 0.055 Not significant  
Gender (female vs. male) 1.087 0.795    0.914 0.737   
HBeAg (positive vs. negative) 1.407 0.132    1.216 0.290   
Tumor size (≥5 vs. <5 cm) 1.618 0.024 Not significant   1.618 0.004 1.650 (1.162–2.342) 0.005
Tumor number (multiple vs. single) 2.175 0.010 Not significant   1.796 0.028 2.104 (1.218–3.635) 0.008
Pathologic grades (IV/III/II/I) 1.365 0.070 1.613 (1.129–2.305) 0.009 1.100 0.476   
Microvascular thrombus (yes vs. no) 2.038 0.010 2.688 (1.534–4.710) 0.001 1.128 0.640   
Tumor capsule (without/incomplete/complete) 1.201 0.148    1.030 0.771   
AFP (>25 vs. ≤25 ng/mL) 1.291 0.240    1.030 0.863   
ALT (>40 vs. ≤40 IU/L) 1.064 0.774    1.088 0.621   
AST (>45 vs. ≤45 IU/L) 1.657 0.018 Not significant   1.688 0.002 1.486 (1.057–2.090) 0.023
ALB (≥35 vs. <35 g/L) 0.294 0.008 Not significant   0.633 0.316   
TBIL (>20.5 vs. ≤20.5 μmol/L) 1.566 0.077 Not significant   1.098 0.672   
Prothrombin time (>13.5 vs. ≤13.5 s) 0.867 0.557    0.814 0.283   
Antiviral treatment (yes vs. no) 0.499 0.001 0.475 (0.309–0.729) 0.001 0.710 0.042 Not significant 0.120
Recurrence (yes vs. no) 9.514 <0.001 9.954 (4.781–20.725) <0.001     
  1. OS overall survival, DFS disease-free survival, CI confidence interval, HR hazard ratio, Antiviral group resection plus postsurgical antiviral treatment group, Non-antiviral group resection alone group, HBV hepatitis B virus, SD standard deviation, HBeAg hepatitis B e antigen, TNM tumor-node-metastasis, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB serum albumin, TBIL serum total bilirubin
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us